The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.





Guangzhou Pharmaceutical Company Limited (a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 0874)

Announcement

Reference is made to the announcements dated 26 November 2001 and 29 May 2002. Guangzhou Pharmaceutical Holdings Limited ("GPHL"), the controlling shareholder holding approximately 60.55% interests in the share capital of Guangzhou Pharmaceutical Company Limited (the "Company") as of the date of this announcement has pledged certain state-owned shares of the Company held by it for the reorganization of liabilities owing by Guangzhou Baiyunshan Pharmaceutical Company Limited.

The Company was informed by GPHL, that according to a ruling made by Guangzhou Intermediate People's Court of Guangdong Province on 11 November 2005 ([2005] Sui Zhong Fa Zhi Zi Civil No. 744), 65,110,000 state-owned shares (including 56,010,000 frozen state-owned shares being referred to in the Company's announcement dated 13 April 2005) of the Company, representing approximately 8.03% of the Company's total issued share capital, which have been pledged by GPHL to institutions including Guangzhou Beicheng Rural Credit Cooperative and have been frozen, are going to be sold by public auction.

This announcement is made in accordance with Rule 13.09(2)of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

By order of the Board **He Shuhua** *Company Secretary*

Guangzhou, PRC, 15 November 2005

As at the date of this announcement, the Board of the Company comprises Mr. Yang Rongming, Mr. Zhou Yuejin, Mr. Xie Bin and Mr. Feng Zansheng as executive directors, and Mr. Wu Zhang, Mr. Wong Hin Wing and Mr. Zhang Heyong as independent nonexecutive directors.